AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2022
Jan 19, 2022
31523_dirs_2022-01-19_e1b577e4-3056-4d47-8105-6abceaecc2d7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2022-01-14
Reporting Person: Clark David Michael (Chief People Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-01-14 | Common Stock | A | 59071 | — | Acquired | 207313 | Direct |
| 2022-01-14 | Common Stock | A | 32235 | — | Acquired | 239548 | Direct |
| 2022-01-14 | Common Stock | F | 12684 | $10.53 | Disposed | 226864 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-01-14 | Stock Options (right to buy) | $12.11 | A | 108266 | Acquired | 2032-01-14 | Common Stock (108266) | Direct |
Footnotes
F1: Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock.
F2: The Restricted Stock Units will vest in four equal annual installments beginning on January 3, 2023.
F3: Granted for the achievement of the 2019 PRSU TSR goal as determined by the Board of Directors.
F4: These options vest and become exercisable in a series of installments over a four year period with 25% vesting on January 3, 2023 and the remaining 75% vesting ratably each month thereafter.